Genmab A/S (Genmab A/S) Other Current Payables : $366 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Genmab A/S Other Current Payables?

Genmab A/S's Other Current Payables for the quarter that ended in Mar. 2024 was $366 Mil.

Genmab A/S's quarterly Other Current Payables increased from Sep. 2023 ($335 Mil) to Dec. 2023 ($338 Mil) and increased from Dec. 2023 ($338 Mil) to Mar. 2024 ($366 Mil).

Genmab A/S's annual Other Current Payables increased from Dec. 2021 ($172 Mil) to Dec. 2022 ($244 Mil) and increased from Dec. 2022 ($244 Mil) to Dec. 2023 ($338 Mil).

Genmab A/S Other Current Payables Historical Data

The historical data trend for Genmab A/S's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Other Current Payables Chart

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Payables

Get a 7-Day Free Trial

124.80

148.15

171.71

244.34

337.54

Genmab A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Payables	Get a 7-Day Free Trial															263.66	273.29	335.02	337.54	366.19

Genmab A/S Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Genmab A/S Other Current Payables Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (Genmab A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (NAS:GMAB) » Definitions » Other Current Payables

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GE91:Germany GE9:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.